Author(s): Rodrigus P, de Brouwer P, Raaymakers E
Abstract Share this page
Abstract A total of 250 patients with brain metastases from non-small cell lung cancer (NSCLC) were treated with irradiation of their brain metastases. The median overall survival was 3.1 (95\% CI: 2.7-3.5) months. 32/250 patients presenting with solitary brain metastasis underwent surgical resection. Their 1-year survival rate of 58\% was significantly better than 89/250 patients with a solitary lesion but without surgery (14\%, P=0.001). Patients with an absent or controlled primary tumor (101/250, 40.5\%) had a 1-year survival rate of 26\% as opposed to 11\% for patients presenting with an active primary tumor (P=0.051). Patients presenting with metastases to the brain only showed a significant survival advantage over patients with extracranial metastases (1-year survival of 21\% vs 6\%, P=0.001). Karnofsky performance score, neurofunction status and response to steroids were also identified as prognostic factors. The total dose whole brain irradiation (WBI) was prognostic of significance with a 1-year survival of 35\% for 30 Gy and boost, 23.5\% for 30 Gy and 4\% for the patients irradiated to a dose of 20 Gy WBI (P=0.001). When patients were grouped into the RTOG RPA (Recursive partitioning analysis) classes, patients within class I (73/250) had a 1-year survival of 28.5\%, patients in class II (145/250) a survival of 14\% at 1 year and patients into class III only a 6\% 1-year survival rate. In a multivariate analysis, surgical resection, neurofunction class, metastatic extent and WBI dose remained significant prognostic factors. Although survival remains poor, there needs to be a continued interest in these patients, probably by participating in clinical trials.
This article was published in Lung Cancer
and referenced in Journal of Pulmonary & Respiratory Medicine